Our purpose is to provide products and services to improve the quality of life of people. We use science and technology to address existing healthcare issues.
Yuyu Pharma R&D Center was established with the aim of developing innovative products for patients.
The Research and Development Center of Yuyu Pharma was established in 1989 with the goal of developing new drugs, as well as improving the efficacy and formulation of existing drug products. In addition, the R&D center collaborates with the Business Development team to license in new products and manage existing Intellectual Properties.
The Research and Development Center succeeded in developing Bonkey injections using Calcitriol for osteoporosis and commercializing Tanamin injections to improve blood flow using ginkgo leaf extracts. Maxmavil tablets, a unique fixed dose combination drug for osteoporosis treatment developed by Yuyu R&D, has been successful in the market in the osteoporosis market, mostly dominated by multinational pharmaceutical companies. As a result, in 2006, the company was recognized for its technology by the Ministry of Health.
Since 2005 Yuyu has been designated as a drug manufacturing technology research center by the Ministry of Commerce, Industry and Energy. Yuyu's other focus is in natural health supplement treatments. In addition, Yuyu has been conducting innovative research with Korean and US universities, along with Korea Research Institute to explore new drugs for next-generation diseases.
The R&D Center's ongoing research efforts for new drug development
1989
Opening of Yuyu R&D Center
1994
Affiliation with the University of Wisconsin-Madison R&D Center in the US (Bonky-Osteoporosis treatment)
1994
Selected as the R&D Center for Military Service Exemption
1994~1995
Execution of a task given by Ministry of Science and ICT (Changing the formulation of Calcitriol to an injection drug for osteoporosis treatment)
1994~1996
Execution of a task given by Ministry of Science and ICT (Changing the formulation of an agent that improves blood circulation using Ginkgo biloba extract to an injection agent)
1997
Acquisition of the manufacturing license for ginkgo leaf extract injection (Tanamin Injection) for the first time in Korea
1998
Launching Marvil Tab.(for osteoporosis treatment) through the technical alliance with Gador SA Argentina
2001~2017
Execution of a task given by Ministry of Science and ICT (New drug development for ischemic vascular disease treatment)
2005
The Jang Young-sil Award recipient at Korea New Drug Award in recognition of Maxmarvil
2005~2010
Launching Maxmarvil
Project sponsored by Ministry of Commerce Industry and Energy (Development of a Pharmaceutical Dosage Form manufacturing technology)
2009
The Technology Award recipient at Korea Drug Research Association Awards in recognition of Yuclid Tab.
2014
Execution of a task given by Innopolis Foundation) (Natural substance for body fat reduction)
2015
Execution of a task given by Ministry of Trade, Industry and Energy (New drug development to treat dry eye syndrome through high-purity collagen peptide inflammation suppression mechanism)
2015
Launching the first generic drug of NEWMACOR Soft Capsule (Omega-3-acid ethyl esters 90)
2016
Execution of a task given by Ministry of SMEs and Startups (Development of a new drug compound with improved efficacy for the treatment of benign prostatic hyperplasia with global competitiveness)
2016
Launching DUSTAR Soft Capsule (Dutasteride) Dutasteride Soft Capsule in the smallest size in Korea
2017
Relocation of the Central R&D Center
1981
Begin
2000
2010
Between
Present
Arrive
